Condition: Ovarian Cancer · Solid Tumor · Sponsor: OnCusp Therapeutics, Inc.
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
This description comes directly from the study's public registry record.
Priya Marreddy · (610)256-5979 · Priya.Marreddy@oncusptx.com
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Mount Sinai Medical Center | Miami Beach, Florida, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| NYU Cancer Institute Clinical Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | Houston, Texas, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06234423